Shots:
- Resmed received FDA clearance for its AI-enabled Smart Comfort for PTCS (Personalized Therapy Comfort Settings), the first FDA-cleared device for personalized comfort settings for obstructive sleep apnea (OSA) pts start and stay on CPAP therapy
- US rollout begins in limited beta versions for new users of myAir users in early 2026, followed by broader availability later in 2026
- Retrospective RWE showed higher adherence in users whose settings matched Smart Comfort recommendations in Resmed AirSense 10 and 11 users compared to those using default settings
Ref: Resmed | Image: Resmed | Press Release
Related News: Cardiawave Receives CE Mark for Valvosoft to Treat Severe Symptomatic Aortic Stenosis
PharmaShots, your go-to media platform for customized news across multiple therapeutic areas. For more information, reach us at connect@pharmashots.com
